P Palthera
Signalling Peptides

Cartalax

AED / Ala-Glu-Asp / Alanyl-glutamyl-aspartic acid

Cartalax is a short (Ala-Glu-Asp / AED) developed by the Khavinson research group in St Petersburg. Published evidence is , primarily organotypic and cell-culture work, and is concentrated within the Khavinson network. There are no FDA, MHRA, or EMA approvals.

Add to comparison Subscribe
Abstract reference visual for Signalling Peptides.
Signalling Peptides
Classification
Khavinson short peptide · Ala-Glu-Asp tripeptide · Preclinical only
Research stage
Preclinical (cell-culture) literature from a single research network
Sequence
AED (Ala-Glu-Asp)
Molecular weight
Approximately 333 Da

Snapshot

Key takeaways

A three-bullet snapshot before reading the full dossier.

  1. 01

    Short (Ala-Glu-Asp) developed by the Khavinson group.

  2. 02

    Published evidence is — organotypic and cell-culture studies.

  3. 03

    Peer-reviewed literature is concentrated within a single research network; independent replication is limited.

Dossier overview

3

research areas

2

references

3

handling notes

01

Mechanism of action

Cited work reports AED-associated changes in cell-renewal and gene-expression markers (IGF1, FOXO1, TERT, TNKS2, NFκB) in mesenchymal stem-cell aging cultures and in kidney organotypic models. identity remains uncharacterised.

02

Research applications

  • Mesenchymal stem-cell aging gene-expression studies
  • Kidney tissue organotypic cultures
  • Cell-renewal pathway

Evidence at a glance

What's behind this profile

2 citations · 2015–2020

In vitro
2

Cell, tissue, or biochemical assays outside a living organism.

Publication years

  1. 15
  2. 16
  3. 17
  4. 18
  5. 19
  6. 20
20152020

Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 0 of 2 citations. Findings remain model-specific and are not extrapolated to therapeutic use.

03

Study references

Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.

Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides

2020

Ashapkin V, Khavinson V, Shilovsky G, Linkova N, Vanuyshin B · Molecular Biology Reports

Model
In vitro — human embryo bone-marrow mesenchymal stem cells (FetMSCs line) in passage and stationary aging models
Sample
Not reported in abstract

Reported AED (Cartalax), KED, and KE modulated IGF1, FOXO1, TERT, TNKS2, and NFκB in MSC aging cultures.

PMID 32399807 DOI 10.1007/s11033-020-05543-y

Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals

2015

Chalisova NI, Lin'kova NS, Nichik TE, Ryzhak AP, Dudkov AV, Ryzhak GA · Bulletin of Experimental Biology and Medicine

Model
In vitro — organotypic kidney tissue cultures from young and old rats
Sample
Not reported in abstract

Reported short peptides including AED (T-31) modulated cell-renewal markers in organotypic kidney cultures from young and old rats.

PMID 26033601 DOI 10.1007/s10517-015-2912-y

Evidence caveats

  • No controlled human trials indexed on PubMed at time of writing.
  • All cited primary evidence originates from the Khavinson research network in St Petersburg; independent replication is limited.
  • Findings are model-specific (organotypic / cell-culture) and are not extrapolated to therapeutic use.

04

Storage and handling

Typically stored in a cool, dry environment under controlled laboratory conditions per supplier documentation.

  • Use supplier documentation for batch-specific handling.
  • Limit repeated cycles during research inventory handling.
  • Document date and storage condition where applicable.